share_log

Piper Sandler Initiates Coverage On Cue Biopharma With Overweight Rating, Announces Price Target of $7

Benzinga Real-time News ·  Nov 21, 2022 05:08

Piper Sandler analyst Edward Tenthoff initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Overweight rating and announces Price Target of $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment